- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | EXTRAWELL PHAR (00858): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 27.03. | EXTRAWELL PHAR (00858): MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE SALE OF THE CONVERTIBLE BONDS | - | HKEx | ||
| 17.03. | EXTRAWELL PHAR (00858): COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION ... | - | HKEx | ||
| 27.02. | EXTRAWELL PHAR (00858): (1) EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) DELAY IN ... | - | HKEx | ||
| 20.01. | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 20.01. | EXTRAWELL PHAR (00858): CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 31.12.25 | EXTRAWELL PHAR (00858): CHANGE OF BUILDING NAME OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 2 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY ... | 3 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): CHANGE OF CHIEF EXECUTIVE OFFICER | 3 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): INTERIM REPORT 2025/26 | 1 | HKEx | ||
| 19.12.25 | EXTRAWELL PHAR (00858): GRANT OF SHARE OPTIONS | 2 | HKEx | ||
| 02.12.25 | EXTRAWELL PHAR (00858): MAJOR TRANSACTION - PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS | - | HKEx | ||
| 28.11.25 | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025 | 1 | HKEx | ||
| 20.11.25 | EXTRAWELL PHAR (00858): PROFIT WARNING | 2 | HKEx | ||
| 13.11.25 | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 1 | HKEx |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 65,56 | +0,71 % | Ionis exec shares method to the Madness after 2026 Drug Name Tournament win | ||
| CSPC PHARMA | 1,000 | -1,81 % | CSPC PHARMA SYS6051 Drug Approved for Clinical Trials in China | ||
| SELLAS LIFE SCIENCES | 4,130 | -0,48 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,700 | -1,36 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,285 | -0,92 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 435,50 | -0,82 % | Madrigal Pharmaceuticals-Aktie +12%: Kommt's zur Übernahme? | Die Aktie des US-Pharmaunternehmens Madrigal Pharmaceuticals hat einen kräftigen Kurssprung verzeichnet, nachdem Spekulationen über eine mögliche Übernahme durch den Pharmariesen Eli Lilly aufkamen.... ► Artikel lesen | |
| OPUS GENETICS | 4,760 | -0,42 % | Opus Genetics, Inc.: Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets | Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,820 | -2,43 % | Savara to present molgramostim data at ATS conference in May | ||
| GALECTIN THERAPEUTICS | 2,100 | -2,78 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 3,430 | +4,89 % | XFRA 5MP2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIODEXA PHARMA ADR... ► Artikel lesen | |
| CIPHER PHARMACEUTICALS | 11,500 | -2,54 % | Cipher Pharmaceuticals übertrifft Gewinnerwartungen, verfehlt aber Umsatzziel | ||
| NEURIZON THERAPEUTICS | 0,044 | 0,00 % | NEURIZON THERAPEUTICS LIMITED: Neurizon Investor Briefings Invitation | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| VASO | - | - | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025 | PLAINVIEW, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.